Fluoxetine treatment of obsessive-compulsive disorder

An open clinical trial

Michael R. Liebowitz, Eric Hollander, Schneier Frank, Campeas Raphael, Hatterer Julie, Papp Laszlo, Fairbanks Janet, Sandberg Diana, Davies Sharon, Stein Maria

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

The selective serotonin reuptake blocker fluoxetine was administered to 49 patients with obsessivecompulsive disorder in a 12-week open clinical trial. A minimum adequate trial of at least 8 weeks of treatment was completed by 39 patients. Response rates were 62% (24/39) of adequately treated patients and 49% (24/49) of the whole sample. These uncontrolled findings suggest that fluoxetine is of significant benefit for a substantial proportion of obsessive-compulsive disorder patients. However, controlled trials comparing fluoxetine with placebo and other active agents are needed to confirm this, as are studies aimed to delineate fluoxetine’s full dose range, optimal length of treatment and relapse rate following discontinuation.

Original languageEnglish (US)
Pages (from-to)423-427
Number of pages5
JournalJournal of Clinical Psychopharmacology
Volume9
Issue number6
StatePublished - 1989
Externally publishedYes

Fingerprint

Fluoxetine
Obsessive-Compulsive Disorder
Clinical Trials
Therapeutics
Serotonin
Placebos
Recurrence

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Liebowitz, M. R., Hollander, E., Frank, S., Raphael, C., Julie, H., Laszlo, P., ... Maria, S. (1989). Fluoxetine treatment of obsessive-compulsive disorder: An open clinical trial. Journal of Clinical Psychopharmacology, 9(6), 423-427.

Fluoxetine treatment of obsessive-compulsive disorder : An open clinical trial. / Liebowitz, Michael R.; Hollander, Eric; Frank, Schneier; Raphael, Campeas; Julie, Hatterer; Laszlo, Papp; Janet, Fairbanks; Diana, Sandberg; Sharon, Davies; Maria, Stein.

In: Journal of Clinical Psychopharmacology, Vol. 9, No. 6, 1989, p. 423-427.

Research output: Contribution to journalArticle

Liebowitz, MR, Hollander, E, Frank, S, Raphael, C, Julie, H, Laszlo, P, Janet, F, Diana, S, Sharon, D & Maria, S 1989, 'Fluoxetine treatment of obsessive-compulsive disorder: An open clinical trial', Journal of Clinical Psychopharmacology, vol. 9, no. 6, pp. 423-427.
Liebowitz, Michael R. ; Hollander, Eric ; Frank, Schneier ; Raphael, Campeas ; Julie, Hatterer ; Laszlo, Papp ; Janet, Fairbanks ; Diana, Sandberg ; Sharon, Davies ; Maria, Stein. / Fluoxetine treatment of obsessive-compulsive disorder : An open clinical trial. In: Journal of Clinical Psychopharmacology. 1989 ; Vol. 9, No. 6. pp. 423-427.
@article{ad20df9e0db74dd98944ee8a5544e3c8,
title = "Fluoxetine treatment of obsessive-compulsive disorder: An open clinical trial",
abstract = "The selective serotonin reuptake blocker fluoxetine was administered to 49 patients with obsessivecompulsive disorder in a 12-week open clinical trial. A minimum adequate trial of at least 8 weeks of treatment was completed by 39 patients. Response rates were 62{\%} (24/39) of adequately treated patients and 49{\%} (24/49) of the whole sample. These uncontrolled findings suggest that fluoxetine is of significant benefit for a substantial proportion of obsessive-compulsive disorder patients. However, controlled trials comparing fluoxetine with placebo and other active agents are needed to confirm this, as are studies aimed to delineate fluoxetine’s full dose range, optimal length of treatment and relapse rate following discontinuation.",
author = "Liebowitz, {Michael R.} and Eric Hollander and Schneier Frank and Campeas Raphael and Hatterer Julie and Papp Laszlo and Fairbanks Janet and Sandberg Diana and Davies Sharon and Stein Maria",
year = "1989",
language = "English (US)",
volume = "9",
pages = "423--427",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Fluoxetine treatment of obsessive-compulsive disorder

T2 - An open clinical trial

AU - Liebowitz, Michael R.

AU - Hollander, Eric

AU - Frank, Schneier

AU - Raphael, Campeas

AU - Julie, Hatterer

AU - Laszlo, Papp

AU - Janet, Fairbanks

AU - Diana, Sandberg

AU - Sharon, Davies

AU - Maria, Stein

PY - 1989

Y1 - 1989

N2 - The selective serotonin reuptake blocker fluoxetine was administered to 49 patients with obsessivecompulsive disorder in a 12-week open clinical trial. A minimum adequate trial of at least 8 weeks of treatment was completed by 39 patients. Response rates were 62% (24/39) of adequately treated patients and 49% (24/49) of the whole sample. These uncontrolled findings suggest that fluoxetine is of significant benefit for a substantial proportion of obsessive-compulsive disorder patients. However, controlled trials comparing fluoxetine with placebo and other active agents are needed to confirm this, as are studies aimed to delineate fluoxetine’s full dose range, optimal length of treatment and relapse rate following discontinuation.

AB - The selective serotonin reuptake blocker fluoxetine was administered to 49 patients with obsessivecompulsive disorder in a 12-week open clinical trial. A minimum adequate trial of at least 8 weeks of treatment was completed by 39 patients. Response rates were 62% (24/39) of adequately treated patients and 49% (24/49) of the whole sample. These uncontrolled findings suggest that fluoxetine is of significant benefit for a substantial proportion of obsessive-compulsive disorder patients. However, controlled trials comparing fluoxetine with placebo and other active agents are needed to confirm this, as are studies aimed to delineate fluoxetine’s full dose range, optimal length of treatment and relapse rate following discontinuation.

UR - http://www.scopus.com/inward/record.url?scp=0024847610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024847610&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 423

EP - 427

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 6

ER -